Maxim Group Lowers Context Therapeutics (NASDAQ:CNTX) Price Target to $4.00

Context Therapeutics (NASDAQ:CNTX) had its price objective decreased by Maxim Group from $8.00 to $4.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Maxim Group’s target price would suggest a potential upside of 490.84% from the company’s current price.

Other equities analysts have also issued reports about the stock. D. Boral Capital reiterated a “buy” rating and issued a $9.00 price target on shares of Context Therapeutics in a research note on Tuesday, March 24th. Lifesci Capital upgraded shares of Context Therapeutics to a “strong-buy” rating in a research note on Monday, February 23rd. Wall Street Zen lowered shares of Context Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Context Therapeutics in a research note on Monday, April 20th. Finally, Guggenheim reiterated a “buy” rating and issued a $5.00 price target on shares of Context Therapeutics in a research note on Tuesday, March 24th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $6.17.

Context Therapeutics Price Performance

Shares of CNTX stock traded down $0.00 during trading hours on Tuesday, reaching $0.68. 4,507,238 shares of the stock were exchanged, compared to its average volume of 1,424,900. The firm has a market capitalization of $62.20 million, a P/E ratio of -1.61 and a beta of 1.61. Context Therapeutics has a 12-month low of $0.56 and a 12-month high of $3.62. The business’s fifty day moving average is $2.30 and its two-hundred day moving average is $2.10.

Context Therapeutics (NASDAQ:CNTX) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.03. As a group, equities research analysts predict that Context Therapeutics will post -0.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Context Therapeutics

Large investors have recently modified their holdings of the company. XTX Topco Ltd boosted its holdings in shares of Context Therapeutics by 858.8% in the fourth quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock valued at $149,000 after acquiring an additional 91,008 shares during the period. Quadrature Capital Ltd acquired a new stake in shares of Context Therapeutics in the fourth quarter valued at approximately $68,000. Marshall Wace LLP boosted its holdings in shares of Context Therapeutics by 7,153.7% in the fourth quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock valued at $3,812,000 after acquiring an additional 2,557,448 shares during the period. State Street Corp lifted its holdings in shares of Context Therapeutics by 8.5% during the fourth quarter. State Street Corp now owns 165,607 shares of the company’s stock worth $243,000 after purchasing an additional 13,000 shares during the period. Finally, Renaissance Technologies LLC lifted its holdings in shares of Context Therapeutics by 58.8% during the fourth quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock worth $747,000 after purchasing an additional 188,202 shares during the period. 14.03% of the stock is owned by institutional investors and hedge funds.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.